What’s Next for Liquid Biopsy Tests?
Foresight Diagnostics CEO and CSO Jake Chabon gives an overview of what’s next for liquid biopsy testing, and how it will impact the continuum of care.
Read MorePosted by Chris Wolski | Sep 20, 2021 | Lymphoma |
Foresight Diagnostics CEO and CSO Jake Chabon gives an overview of what’s next for liquid biopsy testing, and how it will impact the continuum of care.
Read MorePosted by Toni Mitchell | Sep 20, 2021 | Lung Cancer |
The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic.
Read MorePosted by Toni Mitchell | Sep 14, 2021 | Lung Cancer |
A recent report showed less than half of community oncologists used biomarker testing for lung cancer — compared to 73% of academic clinicians.
Read MorePosted by Chris Wolski | Sep 3, 2021 | Disease States |
New research has uncovered a precision medicine test to identify a patient subgroup of a rare blood disorder who are more likely to respond to treatment.
Read MorePosted by Chris Wolski | Sep 2, 2021 | Prostate |
During the pandemic, studies have shown many men are missing or delaying routine health screenings, including prostate cancer screenings.
Read More